LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model

Figure 3

Anti-HER-2/neu antibody levels. Serum obtained from mice from the experiment shown in Figure 1 on day 7 after tumor challenge (collected on day 28 after the first vaccination) was evaluated by ELISA at two serum dilutions for antibody to HER-2/neu. Mice that were unimmunized and unchallenged provided the control serum (“nontumor”). Nontumor: 1 (1 : 10), 2 (1 : 100); tumor only: 3 (1 : 10), 4 (1 : 100); tumor + vaccine: 5 (1 : 10), 6 (1 : 100).